CCR5 inhibition in colorectal cancer patients

被引：3
|
作者：
Halama, Niels [1 ]
机构：
[1] Univ Heidelberg Hosp, Dept Med Oncol & Internal Med 6, Natl Ctr Tumor Dis, Heidelberg, Germany
来源：
TRANSLATIONAL CANCER RESEARCH | 2016年 / 5卷
关键词：
IMMUNOTHERAPY; RECEPTOR; THERAPY; TARGET;
D O I：
10.21037/tcr.2016.07.42
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S366 / S367
页数：2
相关论文
共 50 条
  • [41] CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1
    Lorenzen, Thore
    Stoehr, Albrecht
    Walther, Irene
    Plettenberg, Andreas
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (09) : 419 - 425
  • [42] CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1
    Bredeek, U. Fritz
    Harbour, Michael J.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (09) : 427 - 434
  • [43] Corneal neovascularization: Transient inhibition by genetic ablation of CCR2 and sustained inhibition by CCR5 ablation
    Ambati, BK
    Ambati, J
    Joussen, AM
    Anand, A
    Kuziel, WA
    Adamis, AP
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2002, 43 : U399 - U399
  • [44] Role of genetic polymorphisms in CCL5/CCR5 axis to predict efficacy of regorafenib in patients with refractory metastatic colorectal cancer.
    Suenaga, Mitsukuni
    Schirripa, Marta
    Cao, Shu
    Zhang, Wu
    Yang, Dongyun
    Marmorino, Federica
    Bergamo, Francesca
    Antoniotti, Carlotta
    Rossini, Daniele
    Ning, Yan
    Okazaki, Satoshi
    Berger, Martin D.
    Miyamoto, Yuji
    Gopez, Roel
    Hanna, Diana L.
    Barzi, Afsaneh
    Mashima, Tetsuo
    Yamaguchi, Toshiharu
    Loupakis, Fotios
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [45] The frequency of CCR5 promoter polymorphisms and CCR5 Δ 32 mutation in Iranian populations
    Zare-Bidaki, Mohammad
    Karimi-Googheri, Masoud
    Hassanshahi, Gholamhossein
    Zainodini, Nahid
    Arababadi, Mohammad Kazemi
    IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2015, 18 (04) : 312 - 316
  • [46] Frequency of the CCR5Δ32 allele in Brazilians:: a study in colorectal cancer and in HTLV-I infection
    Pereira, RW
    Pires, ER
    Duarte, APM
    de Moura, RP
    Monteiro, E
    Torloni, H
    Proietti, AB
    Simpson, AJG
    Pena, SDJ
    GENETICS AND MOLECULAR BIOLOGY, 2000, 23 (03) : 523 - 526
  • [47] CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice -: Clinical implications for CCR5 inhibition as antiretroviral therapy -: Reply
    Moreno, C
    Devière, J
    Louis, H
    HEPATOLOGY, 2006, 43 (04) : 879 - 880
  • [48] Expression of CCL5 (RANTES) and CCR5 in prostate cancer
    Vaday, GG
    Peehl, DM
    Kadam, PA
    Lawrence, DM
    PROSTATE, 2006, 66 (02): : 124 - 134
  • [49] Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions
    Nakata, Hirotomo
    Kruhlak, Michael
    Kamata, Wakako
    Ogata-Aoki, Hiromi
    Li, Jianfeng
    Maeda, Kenji
    Ghosh, Arun K.
    Mitsuya, Hiroaki
    ANTIVIRAL THERAPY, 2010, 15 (03) : 321 - 331
  • [50] Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5Δ32
    Benkirane, M
    Jin, DY
    Chun, RF
    Koup, RA
    Jeang, KT
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (49) : 30603 - 30606
12345